Appeal No. 2004-0340 Page 3
Application No. 09/847,121
“The second active ingredient of the compositions . . . is an aldose
reductase inhibitor. Numerous suitable aldose reductase inhibitors are known to
persons skilled in the art.” Page 5. One specific example is quercetin. Page 6,
lines 11-12. “The aldose reductase inhibitor is used in an amount that provides
substantially the same level of aldose reductase inhibition as 13-21.4 mg/kg body
weight of the patient per day of quercetin.” Page 6, lines 24-25.
“Another active ingredient in the compositions . . . is the antioxidant.”
Page 6, lines 31-32. Preferred antioxidants include “ascorbyl palmitate, ascorbic
acid (vitamin C), vitamin A, [and] vitamin E.” Page 7, lines 11-12. “Ascorbyl
palmitate may be used in amounts of 11-28.6 mg/kg body weight of the patient
per day. . . . When vitamin E is employed as mixed tocopherols, an amount of
about 4-11.4 IU per kg body weight of the patient, per day may be employed. . . .
When vitamin A is employed, an amount of about 170-357.1 IU per kg body
weight of the patient, per day, is employed.” Page 7, lines 22-31.
“Dosages may be administered 1-10 times per day. . . . Thus, the
composition of the invention may comprise anywhere from one tenth of the daily
minimum dosage of the various active ingredients up to a maximum of the daily
maximum dosage of the various active ingredients.” Page 10, lines 22-28.
Discussion
The claims are directed to a composition comprising three compounds:
vitamin D3 (or a specific derivative thereof) in an amount effective to promote
synthesis of nerve growth factor; an aldose reductase inhibitor in an amount
effective to inhibit aldose reductase; and “an effective amount of an antioxidant.”
Page: Previous 1 2 3 4 5 6 7 8 9 Next
Last modified: November 3, 2007